July 3, 2012
/PRNewswire/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today that
, Sangamo's president and CEO, will provide an update on the progress of Sangamo's ZFP Therapeutic® development programs and an overview of the company's business strategy at
10:00 am ET
Thursday, July 12, 2012
, at the Seventh Annual JMP Securities Healthcare Conference which will be held in
New York City
The presentation will be webcast live and may be accessed via a link on the Sangamo BioSciences website in the Investor Relations section
under Events and Presentations. The presentation will be archived on the Sangamo website for two weeks after the event.
Sangamo BioSciences, Inc. is focused on research and development of novel DNA-binding proteins for therapeutic gene regulation and genome editing. It has ongoing Phase 2 and Phase 1/2 clinical trials to evaluate the safety and efficacy of a novel ZFP Therapeutic® for the treatment of HIV/AIDS. Sangamo's other therapeutic programs are focused on monogenic diseases, including hemophilia and hemoglobinopathies such as sickle cell anemia and beta-thalassemia, and a program in Parkinson's disease. Sangamo's core competencies enable the engineering of a class of DNA-binding proteins known as zinc finger DNA-binding proteins (ZFPs). Engineering of ZFPs that recognize a specific DNA sequence enables the creation of sequence-specific ZFP Nucleases (ZFNs) for gene modification and ZFP transcription factors (ZFP TFs) that can control gene expression and, consequently, cell function. Sangamo has entered into a strategic collaboration with Shire to develop therapeutics for hemophilia and other monogenic diseases and has established strategic partnerships with companies in non-therapeutic applications of its technology including Dow AgroSciences and Sigma-Aldrich Corporation. For more information about Sangamo, visit the company's website at
ZFP Therapeutic® is a registered trademark of Sangamo BioSciences, Inc.
SOURCE Sangamo BioSciences, Inc.